The next focusIR Investor Webinar takes places on 14th May with guest speakers from WS Blue Whale Growth Fund, Taseko Mines, Kavango Resources and CQS Natural Resources fund. Please register here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksFrontier Ip Regulatory News (FIPP)

Share Price Information for Frontier Ip (FIPP)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 41.50
Bid: 40.00
Ask: 43.00
Change: 0.00 (0.00%)
Spread: 3.00 (7.50%)
Open: 41.50
High: 41.50
Low: 41.50
Prev. Close: 41.50
FIPP Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Half-year results for the 6 months to 31 Dec 2015

9 Mar 2016 07:00

RNS Number : 4693R
Frontier IP Group plc
09 March 2016
 

9 March 2016

AIM: FIPP

 

Frontier IP Group plc

("Frontier IP" or "the Group")

 

Frontier IP Group plc is focused on the commercialisation of intellectual property

Half-yearly results for the six months to 31 December 2015Financial Highlights

· Group revenue quadrupled to £992,000 (2014: £244,000) - principally reflecting a higher gain on the revaluation of investments of £883,000 (2014: £160,000)

 

· Revenue from services increased 30% to £109,000 (2014: £84,000)

 

· Profit before tax of £549,000 (2014: loss of £242,000)

 

· Fair value of the portfolio up 31% to £3,745,000 at 31 December 2015 (30 June 2015: £2,859,000),an increase of 138% year on year (31 December 2014: £1,574,000)

 

· Basic earnings per share of 2.07p (2014: basic loss per share of 1.07p)

 

· Cash balances as at 31 December 2015 of £264,000 (30 June 2015: £636,000; 31 December 2014: £184,000)

 

· Net assets per share increased to 23.0p as at 31 December 2015 (30 June 2015: 20.9p; 31 December 2014: 17.0p)

 

Operational Highlights

· Further progress in funding the portfolio including:

- PulsiV Solar announced its first fundraising

- Nandi Proteins fundraising successfully completed post period-end

 

· First milestone achieved in our strategy of developing relationships internationally with the announcement, in January 2016, of our agreement with Évora University in Portugal

 

Andrew Richmond, Chairman, commented,

"I am pleased to report that we made excellent progress over the first half of the financial year. We continued to actively pursue the growth of our portfolio and this was reflected in a 31% increase in the fair value of our portfolio compared to 30 June 2015 and in a 138% increase compared to 31 December 2014. We have been successful in securing investment in our portfolio with the completion of fundraisings in PulsiV Solar and Nandi Proteins and look forward to seeing further progress within the portfolio. In line with our aim to extend our sources of exploitable IP, we were pleased to announce our agreement with Évora University in Portugal in January this year, our first relationship to be established by the Group with a university outside of the UK. We remain encouraged by the opportunities for growth in our portfolio."

 

Enquiries

 

Frontier IP Group plc

T: 0131 240 1251

Neil Crabb, Chief Executive

Company website: www.frontierip.co.uk

 

Cantor Fitzgerald Europe

(Nominated Adviser and Joint Broker)

T: 020 7894 7000

David Foreman, Catherine Leftley, Corporate Finance

David Banks, Corporate Broking

Peterhouse Corporate Finance Limited

(Joint Broker)

T: 020 7469 0935

Lucy Williams

Kreab

T: 020 7074 1800

Robert Speed, Matthew Jervois

 

 

Notes to Editors:

 

Frontier IP specialises in assisting institutions and companies in the commercialisation and exploitation of their intellectual property. It establishes formal and informal relationships with sources of exploitable IP, principally universities. Its core business is building and growing a portfolio of equity stakes in spin-out companies by taking an active involvement in the commercialisation and funding of these businesses. Frontier IP currently has seventeen companies in its portfolio, which exploit IP from a range of institutions. www.frontierip.co.uk 

 

 

Interim Management Statement

Summary

Frontier IP's core strategy is to generate value by providing best practice IP commercialisation services to institutions and start-ups, by developing a portfolio of companies capable of commercial success and by providing access to capital for these portfolio companies.

I am pleased to report that we made excellent progress in each of these areas in the first half of the financial year. We continued to actively pursue the growth of our portfolio and this was reflected in a 31% increase in the fair value of our portfolio compared to 30 June 2015 and a 138% increase compared to 31 December 2014. We provided access to capital for portfolio companies Pulsiv Solar Limited ("PulsiV Solar") and Nandi Proteins Limited ("Nandi Proteins"), which significantly contributed to increasing total revenue in the half-year.

PulsiV Solar, which provides a pioneering technology which significantly improves the energy efficiency of photovoltaic solar panels, completed its first fundraising and has continued to make good progress since. Its operation is expanding and results from early testing continue to show significant increases in energy generation when compared with conventional inverter technology.

Post period-end, Nandi Proteins completed a further fundraising at a significantly higher valuation - twice the price per share of the previous fundraising announced in November 2014. Interest in its ingredient-replacement technology is growing, as it offers the food industry the potential to address increasing obesity levels.

Our access to sources of intellectual property ("IP") is expanding, and we were pleased to announce in January 2016 our agreement with Universidade de Évora, Portugal ("Évora"), the first such agreement to be established by the Group with a university outside of the UK. Frontier IP has been engaged to accelerate the commercial value of IP developed within or owned by Évora and will receive a share of the equity in each spin-off company created by the university, as well as a share in the licensing revenue it receives.

Opportunities continue to be encouraging and, looking ahead, we expect to see further progress in our portfolio over the remainder of the financial year.

Results

Financial assets at fair value through profit and loss at 31 December 2015 increased to £3,745,000 (30 June 2015: £2,859,000; 31 December 2014: £1,574,000). Revenue from services over the first half increased by 30% to £109,000 (2014: £84,000) while the 306% increase in total revenue to £992,000 (2014: £244,000) reflected higher investment revaluations (unrealised) of £883,000 (2014: £160,000). The profit before tax was £549,000 (2014: loss £242,000). Administrative expenses decreased by 9% to £443,000 (2014: £487,000) primarily reflecting reduced consultancy fees. Basic earnings per share was 2.07p (2014: loss per share of 1.07p).

Cash balances stood at £264,000 as at 31 December 2015 (30 June 2015: £636,000; 31 December 2014: £184,000). Net assets per share as at 31 December 2015 were 23.0p (30 June 2015: 20.9p; 31 December 2014: 17.0p).

Operational Review

We are pleased to report good progress in a number of our portfolio companies during the period, contributing to significant growth in total revenue for the half-year.

The fundraising in PulsiV Solar has enabled it to accelerate the development of its solar inverter technology, with the latest prototype well-advanced. Existing and new IP has been secured and the PulsiV Solar team is expanding with the appointment of its first full time employee. The global solar inverter market is forecast to be valued at approximately $7 billion in 2015 and PulsiV Solar's technology can be integrated into new systems or retrofitted to existing solar panels.

Post period-end, we completed a further fundraising in Nandi Proteins, which will enable it to take advantage of the current high level of interest in its technology from multi-national food companies. In particular, the sugar, fat and additive replacement properties of its technology are very relevant at a time when food companies are under increasing legislative pressure to reduce the level of these ingredients in their products. Nandi Proteins is working to scale up its technology to meet this potential demand in the coming year.

Following its first fundraising in early 2015, Alusid Limited ("Alusid") has established a pilot plant, produced its first sample product, SilicaStone, which won Product of the Year - Surfaces at Mixology North, a prestigious interior design awards event and reached the final three in the Innovation category at the Homes & Gardens magazine Designer Awards. Discussions with both suppliers of recyclable raw materials and potential customers are well underway and Alusid will shortly be seeking to raise further funds to enable it to meet projected demand.

Cambridge Sensor Innovation Limited ("CSI"), which exploits a novel sensor technology developed by Dr. Mark Williamson at the Department of Chemical Engineering and Biotechnology at the University of Cambridge, made good progress in developing its next generation sensor technology during the period and a first order for this new generation technology has been received from a global speciality chemicals company. The next challenge for CSI will be to create the capacity to manufacture in larger volumes and it will shortly be seeking third party funding to achieve this goal.

In order to maintain the growth in our portfolio we continue to work with new and existing partners to source and identify new opportunities and are working on a range of pipeline projects.

As stated in the Group's Annual Report & Financial Statements 2015 we anticipate undertaking an equity placing during this second half, using the authorities granted at our most recent Annual General Meeting. This funding will provide ongoing working capital for the Group and support delivery of the strong growth opportunities available to us. 

Outlook

Frontier IP has made encouraging progress over the first half and the continuing growth in value of our portfolio is especially pleasing. We remain very positive about the opportunities within our portfolio and from our sources of exceptional IP and look forward to reporting on further progress over the second half of the financial year.

Neil Crabb

Chief Executive Officer

9 March 2016

CONSOLIDATED STATEMENT OF COMPREHENSIVE INCOME 

For the six months ended 31 December 2015

  

 
 
 
 
Notes
Six months ended 31 December 2015 (unaudited)
 Six months ended 31 December 2014 (unaudited)
Year ended 30 June 2015 (audited)
 
 
£’000
£’000
£’000
Revenue
 
 
 
 
Revenue from services
 
109
84
170
Other operating income
 
 
 
 
Unrealised profit on the revaluation of
 
 
 
 
investments
7
883
160
1,421
Total revenue
 
992
244
1,591
 
 
 
 
 
Administrative expenses
 
(443)
(487)
(945)
Profit/(loss) from operations
 
549
(243)
646
 
 
 
 
 
Interest income on short-term bank deposits
 
-
1
1
Profit/(loss) before tax
 
549
(242)
647
 
 
 
 
 
Taxation
5
-
-
-
 
 
 
 
 
Profit/(loss) and total comprehensive income/(expense) attributable to the equity holders of the parent
 
 
549
 
(242)
647
 
 
 
 
 
 
 
 
 
 
Profit/(loss) per share attributable to the equity
 
 
 
 
holders of the parent
 
 
 
 
Basic earnings/(loss) per share
6
2.07p
(1.07)p
2.76p
Diluted earnings/(loss) per share
6
2.05p
(1.05)p
2.71p
 

All of the Group's activities are classed as continuing and there were no comprehensive gains or losses in any period other than those included in the statement of comprehensive income.

 

 

CONSOLIDATED STATEMENT OF FINANCIAL POSITION 

At 31 December 2015

 As at 31 December

2015 (unaudited)

£'000

 As at 31 December

2014 (unaudited)

£'000

As at

30 June

2015 (audited)

£'000

ASSETS

Notes

Non-current assets

Tangible fixed assets

1

2

2

Goodwill

1,966

1,966

1,966

Financial assets at fair value through profit and loss

7

3,745

1,574

2,859

Trade receivables

117

84

29

5,829

3,626

4,856

Current assets

Trade receivables and other current assets

Cash and cash equivalents

 

154

264

 

145

184

 

188

636

418

329

824

Total assets

6,247

3,955

5,680

LIABILITIES

Current liabilities

Trade and other payables

(128)

(119)

(123)

(128)

(119)

(123)

 

Net assets

 

6,119

 

3,836

 

5,557

EQUITY

Called up share capital

Share premium account

Reverse acquisition reserve

Share based payment reserve

Retained earnings

2,660

5,200

(1,667)

58

(132)

2,253

4,794

(1,667)

134

(1,678)

2,660

5,200

(1,667)

45

(681)

 

Total equity

 

6,119

 

3,836

 

5,557

 

CONSOLIDATED STATEMENT OF CHANGES IN EQUITY

For the six month period ended 31 December 2015

 

 

 

Share

 capital

 

Share

premium

account

 

Reverse acquisition

 reserve

Share-

based

payment

 reserve

 

Profit

and loss

account

 

 

 

Total

£'000

£'000

£'000

£'000

£'000

£'000

At 1st July 2014

2,253

4,794

(1,667)

125

(1,436)

4,069

Share-based payments

-

-

-

9

-

9

(Loss)/comprehensive expense for the period

-

-

-

-

(242)

(242)

At 31 December 2014

2,253

4,794

(1,667)

134

(1,678)

3,836

Issue of shares

407

406

-

-

-

813

Share-based payments

-

-

-

19

-

19

Transfer on expiry of warrants in prior year

-

-

-

(108)

108

-

Profit/comprehensive income for the period

-

-

-

-

889

889

At 30 June 2015

2,660

5,200

(1,667)

45

(681)

5,557

Share-based payments

-

-

-

13

-

13

Profit/comprehensive income for the period

-

-

-

-

549

549

At 31 December 2015

2,660

5,200

(1,667)

58

(132)

6,119

 

CONSOLIDATED STATEMENT OF CASH FLOWS

For the six months ended 31 December 2015

Six months ended 31 December

2015 (unaudited)

£'000

Six months ended 31 December

2014 (unaudited)

£'000

Year ended 30 June

2015 (audited)

£'000

Cash flows from operating activities

Cash used in operations

(369)

(315)

(730)

Taxation paid

-

-

-

Net cash used in operating activities

(369)

(315)

(730)

Cash flows from investing activities

Purchase of tangible fixed assets

-

-

(1)

Purchase of financial assets at fair value through profit and loss

 

(3)

 

(89)

 

(33)

Interest received

-

1

-

Net cash used in investing activities

 

(3)

(88)

(34)

 

Cash flows from financing activities

Proceeds from issue of equity shares

Costs of share issue

 

 

-

-

 

 

-

-

 

 

854

(41)

Net cash generated from financing activities

-

-

813

 

Net (decrease)/increase in cash and cash equivalents

 

(372)

 

(403)

 

49

Cash and cash equivalents at beginning of period

636

587

587

Cash and cash equivalents at end of period

264

184

636

Cash used in operations

Profit/(loss) before tax

549

(242)

647

Adjustments for:

Share-based payments

13

9

28

Depreciation

1

-

2

Costs of share issue

-

-

-

Fair value (gain) on financial assets at fair value through profit or loss

 

(883)

 

(160)

 

(1,421)

Changes in working capital:

Trade and other receivables

(55)

224

1

Trade and other payables

6

(146)

13

(369)

(315)

(730)

 

NOTES

1. General information

The Company is a limited liability company incorporated in England and with its registered office at NorthWest Wing, Bush House, Aldwych, London WC2B 4EZ. The Company's trading office is situated at 93 George Street, Edinburgh EH2 3ES.

The Company is quoted on the AIM market.

This condensed consolidated interim financial information was approved and authorised for issue by a duly appointed and authorised committee of the Board of Directors on 8 March 2016.

This condensed interim financial information has not been audited or reviewed by the Company's auditor.

2. Basis of preparation

This condensed consolidated interim financial information for the six months ended 31 December 2015 has been prepared in accordance with International Accounting Standard 34 "Interim Financial Reporting". The condensed consolidated interim financial information should be read in conjunction with the annual financial statements for the year ended 30 June 2015, which have been prepared in accordance with International Financial Reporting Standards (IFRS) as adopted by the EU.

This condensed consolidated interim financial information does not constitute statutory accounts within the meaning of section 434 of the Companies Act 2006. The comparatives for the full year ended 30 June 2015 are not the Company's full statutory accounts for that year. A copy of the statutory accounts for that year has been delivered to the Registrar of Companies. The auditor's report on those accounts was unqualified, contained an emphasis of matter with respect to going concern, and did not contain a statement under sections 498(2) or 498(3) of the Companies Act 2006.

3. Accounting policies

The accounting policies applied by the Group in these unaudited half year results are consistent with those applied in the annual financial statements for the year ended 30 June 2015 as described in the Group's Annual Report for that year and as available on our website www.frontierip.co.uk. No new standards that have become effective in the period have had a material effect on the Group's financial statements.

Taxes on income in the interim periods are accrued using the tax rate that would be applicable to expected total annual earnings.

 

4. Segmental information

The chief operating decision-maker has been identified as the Group's board of directors. The board reviews the Group's internal reporting in order to assess performance and allocate resources. Currently the board considers that the Group has one operating activity, the commercialisation of University IP. All of the Group's activities are carried out in the UK.

5. Taxation

The taxation expense is recognised based on management's best estimate of the weighted average annual tax rate expected for the full financial year. Management expects that there will be no tax charge arising in the year and so there is no charge to taxation for the six months to 31 December 2015 (2014: Nil).

A deferred tax asset has not been recognised in respect of losses in view of the uncertainty as to the level of future taxable profits.

6. Earnings/(loss) per share

The calculation of the basic earnings / (loss) per share for the six months ended 31 December 2015 and 31 December 2014 and for the year ended 30 June 2015 is based on the earnings / (losses) attributable to the shareholders of Frontier IP Group plc in each period divided by the weighted average number of shares in issue during the period.

Basic earnings/(loss) per share

 

Earnings/(loss) attributable to shareholders

Weighted average number of shares

 

Basic earnings/(loss)

per share

£'000

Number

Pence

Six months ended 31 December 2015

549

26,601,020

2.07

Six months ended 31 December 2014

(242)

22,534,353

(1.07)

Year ended 30 June 2015

647

23,414,536

2.76

Diluted earnings/(loss) per share

 

Earnings/(loss) attributable to shareholders

Weighted average number of shares

 

Diluted earnings/(loss)

per share

£'000

Number

Pence

Six months ended 31 December 2015

549

26,808,407

2.05

Six months ended 31 December 2014

(242)

23,112,885

(1.05)

Year ended 30 June 2015

647

23,854,707

2.71

 

7. Financial Assets at Fair Value Through Profit and Loss

31 December

31 December

30 June

2015

2014

2015

£'000

£'000

£'000

Opening balance

2,859

1,325

1,325

Additions

3

89

113

Fair value increase

883

160

1,421

Closing balance

3,745

1,574

2,859

 

8. Copies of Half Yearly Report

Copies of the Half Yearly Report will be available on the Company's website, www.frontierip.co.uk, and on request from the Company's offices at 93 George Street, Edinburgh EH2 3ES no later than 11th March 2016.

 

 

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
IR BIGDXXSGBGLI
Date   Source Headline
7th May 202410:15 amRNSTVG to collaborate with The Pirbright Institute
2nd May 20247:00 amRNSFrontier IP announces stake in DiaGen
17th Apr 20241:59 pmRNSHolding(s) in Company
12th Apr 20247:00 amRNSAppointment of Chief Financial Officer
2nd Apr 202412:44 pmRNSHolding(s) in Company
14th Mar 20247:00 amRNSUnaudited Half Year Results
4th Mar 20241:40 pmRNSHolding(s) in Company
29th Feb 20243:12 pmRNSSale of shares in Exscientia
30th Jan 202411:45 amRNSHolding(s) in Company
22nd Jan 20247:00 amRNSOctopus invest in Alusid as part of equity funding
29th Dec 202312:00 pmRNSTotal Voting Rights
19th Dec 20234:46 pmRNSHolding(s) in Company
15th Dec 20236:12 pmRNSReplacement - Result of AGM and Directorate Change
15th Dec 20232:07 pmRNSResult of AGM and Directorate Change
13th Dec 20237:00 amRNSPortfolio news - The Vaccine Group
11th Dec 20237:00 amRNSHolding(s) in Company
30th Nov 20235:00 pmRNSTotal Voting Rights
30th Nov 20237:00 amRNSExercise of Options & Director/PDMR Shareholdings
28th Nov 20237:00 amRNSBoard Change
21st Nov 20237:00 amRNSPosting of Annual Report and Notice of AGM
9th Nov 20235:27 pmRNSHolding(s) in Company
3rd Nov 20237:05 amRNSGrant of options
1st Nov 20235:48 pmRNSExercise of Options & PDMR Shareholdings & TVR
31st Oct 20237:01 amRNSBoard changes
31st Oct 20237:00 amRNSFinal results for the year ended 30 June 2023
23rd Oct 20237:00 amRNSNew portfolio company Deakin Bio-Hybrid Materials
12th Oct 20232:05 pmRNSHolding(s) in Company
21st Sep 20237:00 amRNSExscientia announces collaboration with Merck
14th Sep 20235:21 pmRNSHolding(s) in Company
14th Sep 20237:00 amRNSExercise of Options & Total Voting Rights
11th Sep 20237:00 amRNSPortfolio news – Pulsiv appoints Chairman and CPO
8th Sep 20237:00 amRNSExercise of Options & Total Voting Rights
10th Aug 20238:45 amRNSPortfolio news – Fieldwork Robotics
24th Jul 20237:00 amRNSPortfolio news – CamGraPhIC loan facility
20th Jul 20235:18 pmRNSHolding(s) in Company
1st Jun 20237:00 amRNSSale of shares in Exscientia
26th May 20236:06 pmRNSHolding(s) in Company
9th May 20237:00 amRNSTopps Tiles launches first Alusid made tile range
21st Apr 20234:00 pmRNSDirectorate Change
20th Apr 20235:26 pmRNSHolding(s) in Company
27th Mar 20235:17 pmRNSHolding(s) in Company
17th Mar 20232:46 pmRNSGrant of options
15th Mar 20237:00 amRNSBoard changes
15th Mar 20237:00 amRNSUnaudited Half Year Results
30th Jan 20237:00 amRNSAlusid in collaboration with Imerys
9th Jan 20237:00 amRNSCelerum appoints David Gladding as CEO
9th Dec 20224:08 pmRNSResult of AGM
7th Dec 20221:25 pmEQSThe Vaccine Group completes two deadly disease vaccination projects
6th Dec 20227:00 amRNSFrontier IP to host Portfolio Demo Day
5th Dec 20227:00 amRNSThe Vaccine Group completes Lassa fever project

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.